266 related articles for article (PubMed ID: 17924344)
1. Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance.
Sun B; Bird A; Young SP; Kishnani PS; Chen YT; Koeberl DD
Am J Hum Genet; 2007 Nov; 81(5):1042-9. PubMed ID: 17924344
[TBL] [Abstract][Full Text] [Related]
2. Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine pompe disease.
Zhang P; Sun B; Osada T; Rodriguiz R; Yang XY; Luo X; Kemper AR; Clay TM; Koeberl DD
Hum Gene Ther; 2012 May; 23(5):460-72. PubMed ID: 22260439
[TBL] [Abstract][Full Text] [Related]
3. Synergistic Efficacy from Gene Therapy with Coreceptor Blockade and a β2-Agonist in Murine Pompe Disease.
Han SO; Li S; Bird A; Koeberl D
Hum Gene Ther; 2015 Nov; 26(11):743-50. PubMed ID: 26417913
[TBL] [Abstract][Full Text] [Related]
4. A new assay for fast, reliable CRIM status determination in infantile-onset Pompe disease.
Wang Z; Okamoto P; Keutzer J
Mol Genet Metab; 2014 Feb; 111(2):92-100. PubMed ID: 24044919
[TBL] [Abstract][Full Text] [Related]
5. Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II.
Franco LM; Sun B; Yang X; Bird A; Zhang H; Schneider A; Brown T; Young SP; Clay TM; Amalfitano A; Chen YT; Koeberl DD
Mol Ther; 2005 Nov; 12(5):876-84. PubMed ID: 16005263
[TBL] [Abstract][Full Text] [Related]
6. Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease.
Messinger YH; Mendelsohn NJ; Rhead W; Dimmock D; Hershkovitz E; Champion M; Jones SA; Olson R; White A; Wells C; Bali D; Case LE; Young SP; Rosenberg AS; Kishnani PS
Genet Med; 2012 Jan; 14(1):135-42. PubMed ID: 22237443
[TBL] [Abstract][Full Text] [Related]
7. Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter.
Sun B; Zhang H; Franco LM; Brown T; Bird A; Schneider A; Koeberl DD
Mol Ther; 2005 Jun; 11(6):889-98. PubMed ID: 15922959
[TBL] [Abstract][Full Text] [Related]
8. Partial phenotypic correction and immune tolerance induction to enzyme replacement therapy after hematopoietic stem cell gene transfer of alpha-glucosidase in Pompe disease.
Douillard-Guilloux G; Richard E; Batista L; Caillaud C
J Gene Med; 2009 Apr; 11(4):279-87. PubMed ID: 19263466
[TBL] [Abstract][Full Text] [Related]
9. Enhanced efficacy from gene therapy in Pompe disease using coreceptor blockade.
Han SO; Li S; Brooks ED; Masat E; Leborgne C; Banugaria S; Bird A; Mingozzi F; Waldmann H; Koeberl D
Hum Gene Ther; 2015 Jan; 26(1):26-35. PubMed ID: 25382056
[TBL] [Abstract][Full Text] [Related]
10. Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine pompe disease.
Sun B; Kulis MD; Young SP; Hobeika AC; Li S; Bird A; Zhang H; Li Y; Clay TM; Burks W; Kishnani PS; Koeberl DD
Mol Ther; 2010 Feb; 18(2):353-60. PubMed ID: 19690517
[TBL] [Abstract][Full Text] [Related]
11. Antibody formation and mannose-6-phosphate receptor expression impact the efficacy of muscle-specific transgene expression in murine Pompe disease.
Sun B; Li S; Bird A; Yi H; Kemper A; Thurberg BL; Koeberl DD
J Gene Med; 2010 Nov; 12(11):881-91. PubMed ID: 20967919
[TBL] [Abstract][Full Text] [Related]
12. Salmeterol enhances the cardiac response to gene therapy in Pompe disease.
Han SO; Li S; Koeberl DD
Mol Genet Metab; 2016 May; 118(1):35-40. PubMed ID: 27017193
[TBL] [Abstract][Full Text] [Related]
13. Teaching tolerance: New approaches to enzyme replacement therapy for Pompe disease.
Cousens LP; Mingozzi F; van der Marel S; Su Y; Garman R; Ferreira V; Martin W; Scott DW; De Groot AS
Hum Vaccin Immunother; 2012 Oct; 8(10):1459-64. PubMed ID: 23095864
[TBL] [Abstract][Full Text] [Related]
14. Improved efficacy of gene therapy approaches for Pompe disease using a new, immune-deficient GSD-II mouse model.
Xu F; Ding E; Liao SX; Migone F; Dai J; Schneider A; Serra D; Chen YT; Amalfitano A
Gene Ther; 2004 Nov; 11(21):1590-8. PubMed ID: 15356673
[TBL] [Abstract][Full Text] [Related]
15. Muscle-specific, liver-detargeted adeno-associated virus gene therapy rescues Pompe phenotype in adult and neonate Gaa
Sellier P; Vidal P; Bertin B; Gicquel E; Bertil-Froidevaux E; Georger C; van Wittenberghe L; Miranda A; Daniele N; Richard I; Gross DA; Mingozzi F; Collaud F; Ronzitti G
J Inherit Metab Dis; 2024 Jan; 47(1):119-134. PubMed ID: 37204237
[TBL] [Abstract][Full Text] [Related]
16. Impaired clearance of accumulated lysosomal glycogen in advanced Pompe disease despite high-level vector-mediated transgene expression.
Sun B; Zhang H; Bird A; Li S; Young SP; Koeberl DD
J Gene Med; 2009 Oct; 11(10):913-20. PubMed ID: 19621331
[TBL] [Abstract][Full Text] [Related]
17. Gene Therapy for Pompe Disease: The Time is now.
Colella P; Mingozzi F
Hum Gene Ther; 2019 Oct; 30(10):1245-1262. PubMed ID: 31298581
[TBL] [Abstract][Full Text] [Related]
18. Low-Dose Liver-Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of ERT via Immune Tolerance Induction.
Han SO; Ronzitti G; Arnson B; Leborgne C; Li S; Mingozzi F; Koeberl D
Mol Ther Methods Clin Dev; 2017 Mar; 4():126-136. PubMed ID: 28344998
[TBL] [Abstract][Full Text] [Related]
19. Optimizing treatment outcomes: immune tolerance induction in Pompe disease patients undergoing enzyme replacement therapy.
Chen HA; Hsu RH; Fang CY; Desai AK; Lee NC; Hwu WL; Tsai FJ; Kishnani PS; Chien YH
Front Immunol; 2024; 15():1336599. PubMed ID: 38715621
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulatory, liver depot gene therapy for Pompe disease.
Bond JE; Kishnani PS; Koeberl DD
Cell Immunol; 2019 Aug; 342():103737. PubMed ID: 29295737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]